Inhibition of JAK-STAT Signaling Inhibits Formation of Neutrophil Extracellular Traps (NETs)
AssigneesThe Brigham and Women's Hospital, Inc., Children's Medical Center Corporation
InventorsRob Sellar, Benjamin Ebert, Ofir Wolach, Kim Martinod, Denisa Wagner
Life of this patent
Estimating the term…
Abstract
The methods described herein include methods for the treatment of subjects who have Clonal Hematopoiesis of Indeterminate Potential (CHIP) or a Philadelphia-negative myeloproliferative neoplasm (MPN), e.g., polycythaemia vera (PV) or essential thrombocythaemia (ET), using inhibitors of JAK-STAT signaling.
Claims20
A method of reducing risk of recurrence of a cardiovascular event in a subject who has had at least one cardiovascular event, the method comprising:
- identifying a subject who has had at least one cardiovascular event;
- determining the JAK2 genotype of the subject;
- selecting a subject who has a Jak2V617F genotype;
- and
- administering to the subject an effective amount of an inhibitor of JAK-STAT signaling.
A method of reducing risk of occurrence or recurrence of a cardiovascular event in a subject, optionally a subject who has Clonal Hematopoiesis of Indeterminate Potential (CHIP), the method comprising administering to the subject an effective amount of an inhibitor of JAK-STAT signaling.
A method of inhibiting formation of NETs in a subject, the method comprising administering to the subject an effective amount of a JAK-STAT inhibitor.
Dependencies are inferred from the claim text.